Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report

Area of Science:

• Endocrinology
• Genetics
• Immunology

Background:

• Congenital generalized lipodystrophy type 4 (CGL4) is a rare genetic disorder caused by PTRF gene mutations, characterized by adipose tissue loss and muscular dystrophy.
• Current treatment strategies focus on managing metabolic complications like insulin resistance and hypertriglyceridemia.

Purpose of the Study:

• To investigate the efficacy and safety of metreleptin, a leptin analog, in treating a pediatric patient with CGL4.
• To assess the impact of metreleptin on metabolic parameters and potential immune responses in CGL4.

Main Methods:

• A six-year-old boy with CGL4 due to a homozygous PTRF mutation was treated with metreleptin.
• Serum triglyceride levels and HOMA-IR were monitored before, during, and after treatment.
• Detection of anti-metreleptin-neutralizing antibodies was performed.

Main Results:

• Metreleptin initially decreased serum triglyceride levels and HOMA-IR within two months.
• Treatment efficacy waned over time, leading to suspension due to anaphylaxis after a dosage increase.
• Serum triglyceride and HOMA-IR levels significantly increased post-suspension, coinciding with detected anti-metreleptin antibodies.

Conclusions:

• Metreleptin demonstrated short-term metabolic benefits in CGL4 but was limited by an adverse immune response (anaphylaxis and antibody formation).
• The development of neutralizing antibodies suggests a mechanism for decreased efficacy and hypersensitivity.
• Further investigation is required to explore long-term metreleptin efficacy and strategies to mitigate immune-related adverse events in CGL4 treatment.